The nation of Zimbabwe has declined a significant US health deal worth 367 million US dollars (272 million pounds) spanning five years due to the United States' request for confidential biological samples.
This rejection became public following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson later clarified that the United States was requesting biological samples for scientific study and commercial gain but was unwilling to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further negotiations to find a deal agreeable to all parties so the country's critical HIV programme can be sustained.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court suspended a related deal with the US after concerns were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
According to statements, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our country would supply the raw materials for medical research with no assurance that the resulting innovations would be available to our population should a future pandemic arise."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This system is intended to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent collaboration might be designed in a manner that respects the independence and dignity of both nations."
Medical Community Response
Medical experts expressed it recognised the government's concerns, but recommended that talks must proceed since a large portion of the country's HIV programmes were funded by international support.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
The situation highlights the ongoing tensions between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.